Comparison 13. (3.1) Nitric oxide donors versus intracervical prostaglandins (all women).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	400	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.47, 0.86]
1.1 Isosorbide dinitrate	1	400	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.47, 0.86]
2 Uterine hyperstimulation with FHR changes	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
2.1 Glyceryl Trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
3 Caesarean section	2	442	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.44, 0.90]
3.1 Isosorbide dinitrate	1	400	Risk Ratio (M‐H, Fixed, 95% CI)	0.58 [0.38, 0.89]
3.2 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.43, 1.55]
4 Serious neonatal morbidity/perinatal death	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
4.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
5 Cervix unfavourable/unchanged after 12‐24 hours	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.59, 2.81]
5.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.59, 2.81]
6 Oxytocin augmentation	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.43, 1.85]
6.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.43, 1.85]
7 Uterine hyperstimulation without FHR changes	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.01, 2.61]
7.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.01, 2.61]
8 Instrumental vaginal delivery	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.07, 14.95]
8.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.07, 14.95]
9 Perinatal death	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
9.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
10 Maternal side effects (headache)	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	10.0 [1.40, 71.32]
10.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	10.0 [1.40, 71.32]